Ventris Announces Launch of Next Generation Biologic, Allocell® AF
News provided by
Share this article
Share this article
NEWPORT BEACH, Calif., April 14, 2021 /PRNewswire/ -- Ventris Medical, a privately held orthobiologics company focused on design, development and commercialization of allografts and synthetic products for improving patient outcomes in Spinal Procedures and Wound Care, today announced the first use of its product Allocell® AF, a next generation osteoinductive fiber allograft. The first implantation of Allocell AF was performed by Dr. Rishi Wadhwa at Specialists Hospital in Shreveport, Louisiana for a spinal fusion procedure.
Allocell AF represents a new class of allograft engineered for enhanced intra-operative handling and increased biologic responsiveness at the defect site. Allocell AF is designed with broad, augmented bone fibers that maximize the surface area, allowing the fibers to better fill the defect site. Each lot of Allocell AF undergoes an